figshare
Browse

sorry, we can't preview this file

12931_2021_1658_MOESM1_ESM.docx (99.09 kB)

Additional file 1 of Metformin use and respiratory outcomes in asthma-COPD overlap

Download (99.09 kB)
journal contribution
posted on 2021-02-27, 05:01 authored by Tianshi David Wu, Ashraf Fawzy, Gregory L. Kinney, Jessica Bon, Maniraj Neupane, Vickram Tejwani, Nadia N. Hansel, Robert A. Wise, Nirupama Putcha, Meredith C. McCormack
Additional file 1: Table S1. Baseline characteristics of included participants by asthma-COPD overlap status (n=3969). Table S2. Adjusted mean difference (95% confidence interval) in change of secondary outcomes from baseline to 5-year follow-up between metformin users and non-users. Table S3. Adjusted mean difference (95% confidence interval) comparing metformin users to non-users for cross-sectional secondary outcomes including participants without follow-up data. Figure S1. STROBE diagram of cohort derivation. Figure S2. Incidence rate ratio (95% confidence interval) comparing metformin users to non-users for exacerbations stratified by alternative alternative asthma-COPD overlap (ACO) definitions (n=3969)

Funding

National Heart, Lung, and Blood Institute U.S. Department of Veterans Affairs National Institute of Environmental Health Sciences National Institute on Minority Health and Health Disparities U.S. Environmental Protection Agency

History

Usage metrics

    Respiratory Research

    Categories

    Keywords

    Asthma-COPD overlapExacerbationsMetformin

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC